Its use in a targeted therapeutic was demonstrated by incorporation as a payload in an antibody–drug conjugate (ADC), which showed mid‐picomolar cytotoxicity against HER2‐expressing cancer cell lines. This evidence concerns the gene ERBB2 and cancer.